1315 Capital II, L.P. - 20 Jan 2026 Form 4 Insider Report for INTERPACE BIOSCIENCES, INC. (IDXG)

Reporting relationship: 10%+ Owner
Issuer ticker: IDXG
Reported as of: 20 Jan 2026
Net transaction value: +$19,000,001
SEC form: 4
Accepted by SEC: 17 Feb 2026, 16:05:12 UTC
Prior SEC filing: 15 Oct 2024
Source filing: View source filing
Reporting owner signature: 1315 Capital II, L.P. By: 1315 Capital GP II, L.P., its general partner; By: 1315 Capital Ultimate Holdings, LLC, its general partner; By: Adele C. Oliva, Sole Member /s/ Adele C. Oliva

Key filing fact

1315 Capital II, L.P. filed Form 4 for INTERPACE BIOSCIENCES, INC. (IDXG) on 17 Feb 2026.

Key facts

This page summarizes 1315 Capital II, L.P.'s Form 4 filing for INTERPACE BIOSCIENCES, INC. (IDXG).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Feb 2026, 16:05.

Change

Previous filing in this sequence was filed on 15 Oct 2024.
Current net transaction value: +$19,000,001.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001730825 Primary reporting owner

1315 Capital II, L.P.

Relationship: 10%+ Owner
Address: C/O INTERPACE BIOSCIENCES, INC., WATERVIEW PLAZA, SUITE 310 2001 ROUTE 46, PARSIPPANY
Signature: 1315 Capital II, L.P. By: 1315 Capital GP II, L.P., its general partner; By: 1315 Capital Ultimate Holdings, LLC, its general partner; By: Adele C. Oliva, Sole Member /s/ Adele C. Oliva
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXG transaction

Common Stock

Conversion of derivative security

Transaction value: $19,000,001
Shares: +9,405,941
Change %
Price: $2.02
Shares after: 9,405,941
Date: 20 Jan 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXG transaction Derivative

Series C Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -19,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 20 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,405,941
Exercise price: $2.02
Footnotes: F1, F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On January 20, 2026, 19,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 9,405,941 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").

Footnote F2

The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.

Footnote F3

These securities are held of record by 1315 Capital II, L.P. (the "Investor"). 1315 Capital GP II, L.P. ("1315 Capital GP") is the general partner of the Investor and 1315 Capital Ultimate Holdings, LLC ("1315 Capital Ultimate") is the general partner of 1315 Capital GP. By virtue of such relationship, each of 1315 Capital GP and 1315 Capital Ultimate may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Footnote F4

Each of 1315 Capital GP and 1315 Capital Ultimate disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F5

The Series C Convertible Preferred Stock had no expiration date.